Chen Mei

Chen Mei

Auto-generated profile, based on publicly available information

Chen Mei

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2024 in Science Advances
Verified
Journal Article
Open access
SZShuanghong Zhu
Shuanghong Zhu
YLYingwan Luo
Yingwan Luo
KLKongfei Li
Kongfei Li
CMChen Mei
Chen Mei
YWYuxia Wang
Yuxia Wang
HTHongyan Tong
Hongyan Tong
Mutant isocitrate dehydrogenases (IDHs) produce R-2-hydroxyglutarate (R-2HG), which inhibits the growth of most acute myeloid leukemia (AML) cells. Here, we showed that necroptosis, a form of programmed cell death, contributed to the antileukemia activity of R-2HG. Mechanistically, R-2HG competitively inhibited the activity of lysine demethylase 2B (KDM2B), an α-ketoglutarate–dependent dioxygenase. KDM2B inhibition increased histone 3 lysine 4 trimethylation levels and promoted the expression of receptor-interacting protein kinase 1 (RIPK1), which consequently caused necroptosis in AML cells. The expression of RIPK3 was silenced because of DNA methylation in IDH-mutant (mIDH) AML cells, resulting in R-2HG resistance. Decitabine up-regulated RIPK3 expression and repaired endogenous R-2HG–induced necroptosis pathway in mIDH AML cells. Together, R-2HG induced RIPK1-dependent necroptosis via KDM2B inhibition in AML cells. The loss of RIPK3 protected mIDH AML cells from necroptosis. Restoring RIPK3 expression to exert R-2HG’s intrinsic antileukemia effect will be a potential therapeutic strategy in patients with AML.

18 January 2023 in Hematological Oncology
Verified
Journal Article
Closed access
CMChen Mei
Chen Mei
LYLi Ye
Li Ye
YRYanling Ren
Yanling Ren
XZXinping Zhou
Xinping Zhou
LMLiya Ma
Liya Ma
HTHongyan Tong
Hongyan Tong

3 February 2025 in Hematological Oncology
Verified
Journal Article
Closed access
GXGaixiang Xu
Gaixiang Xu
XYXingnong Ye
Xingnong Ye
YZYudi Zhang
Yudi Zhang
WWWei Wang
Wei Wang
SZShuanghong Zhu
Shuanghong Zhu
HTHongyan Tong
Hongyan Tong

17 November 2026 in Therapeutic Advances in Hematology
Verified
Journal Article
Open access
YRYanling Ren
Yanling Ren
WLWei Lang
Wei Lang
YXYu Xu
Yu Xu
CMChen Mei
Chen Mei
XHXianbo Huang
Xianbo Huang
HTHongyan Tong
Hongyan Tong
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option for myelodysplastic syndromes (MDS), yet conventional myeloablative conditioning is highly toxic in elderly or frail patients. Objectives: To compare a decitabine-based reduced-toxicity conditioning (RTC) regimen with modified BUCY in higher-risk MDS patients undergoing allo-HSCT in a real-world setting. Design: Single-center retrospective cohort study. Methods: We retrospectively analyzed 82 consecutive MDS patients undergoing first allo-HSCT between September 2022 and June 2025. Thirty-six patients received decitabine-based RTC (decitabine 20 mg/m 2 /day ×3 days with reduced-dose busulfan and fludarabine), while 46 received modified BUCY. End points were overall survival (OS), relapse-free survival (RFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM). Results: The RTC group had higher baseline risks, including older age (median 57 vs. 53 years, P<0.01), higher HCT-CI scores (HCT-CI≥2: 44.4% vs. 10.9%, P<0.01), more prior debulking therapy (83% vs. 54%, P<0.01), and a trend for more TP53 mutations (22% vs. 13%, P=0.06). Despite greater frailty, 2-year outcomes were comparable: OS (80.5% vs. 75.1%, P=0.84), RFS (70.3% vs. 70.6%, P=0.79), CIR (13.5% vs. 9.6%, P=0.70), and NRM (16.1% vs. 22.0%, P=0.88). In multivariable models, the regimen was not significantly associated with OS (HR 0.35, 95% CI, 0.10–1.17; P=0.09), RFS (HR, 0.67; 95% CI, 0.23–1.92; P=0.45). HCT-CI ≥2 predicted higher mortality (HR, 6.32; 95% CI, 1.78–22.37; P=0.004). Conclusion: Despite the higher baseline frailty, decitabine-based RTC regimen achieved survival outcomes comparable to modified BUCY in MDS patients. These findings suggest its potential to expand transplant eligibility, warranting prospective studies.

8 February 2026 in Therapeutic Advances in Hematology
Verified
Journal Article
Open access
XHXianbo Huang
Xianbo Huang
XWXianhui Wu
Xianhui Wu
SWShasha Wang
Shasha Wang
YXYu Xu
Yu Xu
CMChen Mei
Chen Mei
JQJiejing Qian
Jiejing Qian
In haploidentical hematopoietic stem cell transplantation, preexisting donor-specific anti-HLA antibodies (DSAs) in recipients have been associated with graft rejection, poor graft function (PGF), and unfavorable clinical outcomes, with relatively well-established consensus strategies for its management. However, reports on the emergence of de novo DSAs after transplantation and the corresponding therapeutic approaches remain limited. Here, we describe a case of a 14-year-old patient with myelodysplastic syndrome who developed de novo DSAs as early as day 15 post-transplantation, with a peak mean fluorescence intensity of 12,280, which was associated with PGF. To reduce DSA levels, plasma exchange combined with intravenous immunoglobulin and rituximab was administered, followed by a series of interventions including mesenchymal stem cell infusion. These measures facilitated graft function recovery, controlled transplant-related complications, and ultimately led to successful engraftment.